Compare RCAT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | NVAX |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.4M | 1.1B |
| IPO Year | 2017 | 1995 |
| Metric | RCAT | NVAX |
|---|---|---|
| Price | $7.41 | $6.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $12.50 | $10.78 |
| AVG Volume (30 Days) | ★ 6.9M | 3.5M |
| Earning Date | 12-16-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | $7,443,942.00 | ★ $1,064,651,000.00 |
| Revenue This Year | $396.50 | $58.91 |
| Revenue Next Year | $296.06 | N/A |
| P/E Ratio | ★ N/A | $3.17 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $4.58 | $5.01 |
| 52 Week High | $16.70 | $11.55 |
| Indicator | RCAT | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 39.26 |
| Support Level | $8.01 | $6.43 |
| Resistance Level | $8.80 | $6.84 |
| Average True Range (ATR) | 0.60 | 0.22 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 31.72 | 33.33 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.